Why the study?
Does anti-TNF-alpha treatment with adenoviral vector expressing soluble TNF-alpha receptor type I improve myocardial matrix remodeling and diastolic function in transgenic mice overexpressing TNF-alpha?
Population
Transgenic mice with cardiac-specific overexpression of tumor necrosis factor alpha (TNF-alpha) (TNF1.6)
Design
Preclinical
Authors
Loading...
Cautions against clinical use in diastolic HF; leaves open age-specific TNF-α/MMP targeting in human trials.
Does anti-TNF-alpha treatment with adenoviral vector expressing soluble TNF-alpha receptor type I improve myocardial matrix remodeling and diastolic function in transgenic mice overexpressing TNF-alpha?
Anti-TNF-alpha therapy attenuates maladaptive extracellular matrix remodeling and preserves diastolic function in young transgenic mice overexpressing TNF-alpha, suggesting TNF-alpha and MMPs as potential therapeutic targets in heart failure.
Li et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: